胰腺癌新辅助及转化治疗热点聚焦  

Recent progress in surgical treatment of pancreatic cancer

作　　者：田孝东[1] 邓永琪 杨尹默[1] Tian Xiaodong;Deng Yongqi;Yang Yinmo(Department of Hepatobiliary and Pancreatic Surgery,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院肝胆胰外科,北京100034

出　　处：《中华普通外科杂志》2025年第1期23-27,共5页Chinese Journal of General Surgery

摘　　要：胰腺癌是全球范围内严重威胁人类健康的恶性肿瘤之一,发病率和死亡率逐年上升,经济发达地区更为显著。外科治疗的进步对改善胰腺癌患者预后意义重大。本文述评近年来胰腺癌综合治疗策略的进展,强调多学科综合治疗协作组(MDT)诊疗模式、新辅助治疗、转化治疗及其疗效评价对后续外科治疗的指导意义。MDT诊疗模式通过整合多学科优势,为患者提供个体化诊疗方案,提高了胰腺癌患者的手术切除率和生存率。新辅助治疗和转化治疗为中晚期特别是局部进展期胰腺癌患者提供了手术机会,显著改善了患者预后。此外,准确疗效评价对手术指征、时机和方式选择至关重要。Pancreatic cancer is a severe malignant tumor that poses a significant threat to human health worldwide,with its incidence and mortality rates increasing annually,especially in economically developed regions.The progress of surgical treatment is of great significance in improving the prognosis of pancreatic cancer patients.This article reviews the recent progress in surgical treatment strategies for pancreatic cancer,with a particular emphasis on the multidisciplinary team(MDT)approach,neoadjuvant therapy,conversion therapy,and the assessment of the effectiveness of neoadjuvant/conversion therapy.The MDT approach,by integrating the strengths of multiple disciplines,provides personalized treatment plans for patients,improving the resection rate and survival rate of patients with pancreatic cancer.Neoadjuvant and conversion therapy provide surgical opportunities for patients with advanced pancreatic cancer,improving their prognosis.Additionally,accurate assessment of treatment effects is crucial for determining the timing and method of surgery.

关 键 词：胰腺肿瘤 外科手术 多学科综合治疗协作组 新辅助治疗 转化治疗 

分 类 号：R735.9[医药卫生—肿瘤]